Evidence Repository
The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • Gene obtained from curated document aligns with the Allele Registry but not with ClinVar data
  • No CSPEC computed assertion could be determined for this classification!

Variant: NM_000546.6(TP53):c.412G>C (p.Ala138Pro)

CA000166

12376 (ClinVar)

Gene: TP53
Condition: Li-Fraumeni syndrome
Inheritance Mode: Autosomal dominant inheritance
Link to MONDO
UUID: 71e00d77-684f-44ee-8a90-9eba8ffcea8e
Approved on: 2025-06-05
Published on: 2025-07-18

HGVS expressions

NM_000546.6:c.412G>C
NM_000546.6(TP53):c.412G>C (p.Ala138Pro)
NC_000017.11:g.7675200C>G
CM000679.2:g.7675200C>G
NC_000017.10:g.7578518C>G
CM000679.1:g.7578518C>G
NC_000017.9:g.7519243C>G
NG_017013.2:g.17351G>C
ENST00000503591.2:c.412G>C
ENST00000508793.6:c.412G>C
ENST00000509690.6:c.16G>C
ENST00000514944.6:c.133G>C
ENST00000604348.6:c.391G>C
ENST00000269305.9:c.412G>C
ENST00000269305.8:c.412G>C
ENST00000359597.8:c.412G>C
ENST00000413465.6:c.412G>C
ENST00000420246.6:c.412G>C
ENST00000445888.6:c.412G>C
ENST00000455263.6:c.412G>C
ENST00000504290.5:c.16G>C
ENST00000504937.5:c.16G>C
ENST00000505014.5:n.668G>C
ENST00000508793.5:c.412G>C
ENST00000509690.5:c.16G>C
ENST00000510385.5:c.16G>C
ENST00000514944.5:c.133G>C
ENST00000604348.5:c.391G>C
ENST00000610292.4:c.295G>C
ENST00000610538.4:c.295G>C
ENST00000610623.4:c.-66G>C
ENST00000615910.4:c.379G>C
ENST00000617185.4:c.412G>C
ENST00000618944.4:c.-66G>C
ENST00000619186.4:c.-66G>C
ENST00000619485.4:c.295G>C
ENST00000620739.4:c.295G>C
ENST00000622645.4:c.295G>C
ENST00000635293.1:c.295G>C
NM_000546.5:c.412G>C
NM_001126112.2:c.412G>C
NM_001126113.2:c.412G>C
NM_001126114.2:c.412G>C
NM_001126115.1:c.16G>C
NM_001126116.1:c.16G>C
NM_001126117.1:c.16G>C
NM_001126118.1:c.295G>C
NM_001276695.1:c.295G>C
NM_001276696.1:c.295G>C
NM_001276697.1:c.-66G>C
NM_001276698.1:c.-66G>C
NM_001276699.1:c.-66G>C
NM_001276760.1:c.295G>C
NM_001276761.1:c.295G>C
NM_001276695.2:c.295G>C
NM_001276696.2:c.295G>C
NM_001276697.2:c.-66G>C
NM_001276698.2:c.-66G>C
NM_001276699.2:c.-66G>C
NM_001276760.2:c.295G>C
NM_001276761.2:c.295G>C
NM_001126112.3:c.412G>C
NM_001126113.3:c.412G>C
NM_001126114.3:c.412G>C
NM_001126115.2:c.16G>C
NM_001126116.2:c.16G>C
NM_001126117.2:c.16G>C
NM_001126118.2:c.295G>C
NM_001276695.3:c.295G>C
NM_001276696.3:c.295G>C
NM_001276697.3:c.-66G>C
NM_001276698.3:c.-66G>C
NM_001276699.3:c.-66G>C
NM_001276760.3:c.295G>C
NM_001276761.3:c.295G>C
More

Likely Pathogenic

Met criteria codes 5
PS3 PP3 PS4_Supporting PP4_Moderate PM2_Supporting
Not Met criteria codes 18
BS4 BS3 BS1 BP5 BP7 BP2 BP3 BP4 BP1 PS2 PVS1 PP1 PP2 PM6 PM3 PM1 PM4 BA1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen TP53 Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for TP53 Version 2.3.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
TP53 VCEP
The NM_000546.6: c.412G>C variant in TP53 is a missense variant predicted to cause substitution of alanine by proline at amino acid 138 (p.Ala138Pro). This variant has been reported in 1 proband/family meeting Classic LFS criteria. Based on this evidence, this variant scores 1 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; PMID: 9569035). At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, Internal lab contributors). This variant is absent from gnomAD v4.1.0 (PM2_Supporting). In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965). Computational predictor scores (BayesDel = 0.5846; Align GVGD = Class 25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3). In summary, this variant meets the criteria to be classified as likely pathogenic for Li Fraumeni syndrome based on the ACMG/AMP criteria applied, as specified by the ClinGen TP53 VCEP: PS3, PP3, PM2_supporting, PS4_supporting, PP4_moderate. (Bayesian Points: 9; VCEP specifications version 2.3).
Met criteria codes
PS3
In vitro assays performed in yeast and/or human cell lines showed non-functional transactivation and loss of growth suppression activity indicating that this variant impacts protein function (PS3; PMIDs: 12826609, 30224644, 29979965).
PP3
Computational predictor scores (BayesDel = 0.5846; Align GVGD = Class 25) are above recommended thresholds (BayesDel > 0.16 and an Align GVGD Class of > 15), evidence that correlates with impact to TP53 via protein change (PP3).
PS4_Supporting
This variant has been reported in 1 unrelated probands/families meeting Classic LFS criteria. Based on this evidence, this variant scores 1 total points meeting the TP53 VCEP phenotype scoring criteria of 1-1.5 points. (PS4_Supporting; PMID: 9569035).
PP4_Moderate
At least two individuals with this variant were found to have a variant allele fraction of 5-25%, which is a significant predictor of variant pathogenicity (PP4_Moderate, PMID: 34906512, Internal lab contributors).
PM2_Supporting
This variant is absent from gnomAD v4.1.0 (PM2_Supporting).
Not Met criteria codes
BS4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PVS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM6
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM1
This variant does not reside within a region of TP53 that is defined as a mutational hotspot by the ClinGen TP53 VCEP (PM1 not met).
PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
Curation History
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.